Food and Drug Administration

Oncologic Drugs Advisory Committee Meeting

September 14, 2005

AM Session

Celgene Corporation Briefing Material

The statements contained in this document(s) are not those of the FDA, and FDA does not necessarily agree with these statements.
FDA has not made a final determination about the issues to be discussed at the Advisory Committee meeting.

RevlimidŽ (lenalidomide) briefing material

 

Food and Drug Administration

Disclaimer

Portions of these documents may have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552)
 These redacted portions will appear as white space on the screen or on the printed page.

FDA RevlimidŽ Briefing Material

 

Oncologic Drugs Advisory Committee Meeting

September 14, 2005

PM Session

GlaxoSmithKline Briefing Material

The statements contained in this document(s) are not those of the FDA, and FDA does not necessarily agree with these statements.
FDA has not made a final determination about the issues to be discussed at the Advisory Committee meeting.

ArranonŽ (nelarabine) Injection Briefing Material

 

Food and Drug Administration

Disclaimer

Portions of these documents may have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552)
 These redacted portions will appear as white space on the screen or on the printed page.

FDA ArranonŽ Briefing Material

FDA ArranonŽ Errata Sheet